Status:
COMPLETED
Mix Vaccine for Metastatic Kidney Cancer
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborating Sponsors:
Jinan University Guangzhou
Conditions:
Metastasis From Malignant Tumor of Kidney (Disorder)
Reaction - Mixed Vaccine
Eligibility:
All Genders
40-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this study is the safety and efficacy of mix vaccine to small metastases of kidney cancer.
Detailed Description
By enrolling patients with small metastases of kidney cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine. ...
Eligibility Criteria
Inclusion
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length \< 2 cm
- KPS ≥ 70, lifespan \> 6 months
- Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Key Trial Info
Start Date :
November 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03357289
Start Date
November 30 2017
End Date
August 30 2019
Last Update
September 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China, 510665